| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adding radiotherapy to chemotherapy in advanced NSCLC
|
Brower, Vicki
|
|
2017
|
18 |
11 |
p. e645
|
article
|
| 2 |
Adequate SIRT activity dose is as important as adequate chemotherapy dose
|
Braat, Arthur J A T
|
|
2017
|
18 |
11 |
p. e636
|
article
|
| 3 |
Adequate SIRT activity dose is as important as adequate chemotherapy dose – Authors' reply
|
Sharma, Ricky A
|
|
2017
|
18 |
11 |
p. e637
|
article
|
| 4 |
Adjuvant zoledronic acid to treat breast cancer: not for all
|
Costa, Luís
|
|
2017
|
18 |
11 |
p. 1437-1439
|
article
|
| 5 |
An action plan for cancer control in the USA
|
Collingridge, David
|
|
2017
|
18 |
11 |
p. e619
|
article
|
| 6 |
Antibody-drug conjugates: can the payload improve activity in HER2 expressing cancers?
|
Shah, Manish A
|
|
2017
|
18 |
11 |
p. 1433-1434
|
article
|
| 7 |
Cancer, checkpoint inhibitors, and confusion
|
Fernandes, Michael
|
|
2017
|
18 |
11 |
p. e632
|
article
|
| 8 |
Cancer control in Africa: infrastructure, not philanthropy
|
The Lancet Oncology,
|
|
2017
|
18 |
11 |
p. 1423
|
article
|
| 9 |
Cancer in Tinsel Town
|
Lucas, Catherine
|
|
2017
|
18 |
11 |
p. 1443
|
article
|
| 10 |
Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS
|
Kim, Sung-Bae
|
|
2017
|
18 |
11 |
p. e638
|
article
|
| 11 |
Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers
|
Ahn, Daniel H
|
|
2017
|
18 |
11 |
p. 1427-1428
|
article
|
| 12 |
CONVERTed or not: what are the barriers to implementing the evidence?
|
Katz, Matthew S
|
|
2017
|
18 |
11 |
p. e627
|
article
|
| 13 |
CONVERTed or not: what are the barriers to implementing the evidence? – Author's reply
|
Faivre-Finn, Corinne
|
|
2017
|
18 |
11 |
p. e628
|
article
|
| 14 |
Copanlisib in heavily pretreated indolent lymphoma
|
Das, Manjulika
|
|
2017
|
18 |
11 |
p. e650
|
article
|
| 15 |
Correction to Lancet Oncol 2017; 18: 1502–11
|
|
|
2017
|
18 |
11 |
p. e642
|
article
|
| 16 |
Correction to Lancet Oncol 2017; 18: e315–29
|
|
|
2017
|
18 |
11 |
p. e642
|
article
|
| 17 |
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial
|
Beer, Tomasz M
|
|
2017
|
18 |
11 |
p. 1532-1542
|
article
|
| 18 |
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|
Wu, Yi-Long
|
|
2017
|
18 |
11 |
p. 1454-1466
|
article
|
| 19 |
Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial
|
Coleman, Robert
|
|
2017
|
18 |
11 |
p. 1543-1552
|
article
|
| 20 |
Effect of patient choice and hospital competition on service configuration and technology adoption within cancer surgery: a national, population-based study
|
Aggarwal, Ajay
|
|
2017
|
18 |
11 |
p. 1445-1453
|
article
|
| 21 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial
|
Tjan-Heijnen, Vivianne C G
|
|
2017
|
18 |
11 |
p. 1502-1511
|
article
|
| 22 |
Extended adjuvant therapy: the role of subset analyses
|
Pritchard, Kathleen I
|
|
2017
|
18 |
11 |
p. 1431-1433
|
article
|
| 23 |
First-line obinutuzumab for follicular lymphoma
|
Baker, Holly
|
|
2017
|
18 |
11 |
p. e648
|
article
|
| 24 |
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|
Balar, Arjun V
|
|
2017
|
18 |
11 |
p. 1483-1492
|
article
|
| 25 |
Future cancer research priorities in the USA: a Lancet Oncology Commission
|
Jaffee, Elizabeth M
|
|
2017
|
18 |
11 |
p. e653-e706
|
article
|
| 26 |
Implementing the Cancer Moonshot and beyond
|
Lowy, Doug R
|
|
2017
|
18 |
11 |
p. e622-e623
|
article
|
| 27 |
Inpatient palliative care during transplantation
|
Gunjur, Ashray
|
|
2017
|
18 |
11 |
p. e644
|
article
|
| 28 |
Insulin analog linked to breast cancer risk
|
Gourd, Elizabeth
|
|
2017
|
18 |
11 |
p. e646
|
article
|
| 29 |
Is competition bad for our health(care)? We simply don't know
|
Chalkidou, Kalipso
|
|
2017
|
18 |
11 |
p. 1424-1425
|
article
|
| 30 |
Lung cancer screening and its continuous risk assessment
|
de Koning, Harry J
|
|
2017
|
18 |
11 |
p. 1434-1436
|
article
|
| 31 |
Maintenance rituximab in mantle-cell lymphoma
|
Burki, Talha Khan
|
|
2017
|
18 |
11 |
p. e647
|
article
|
| 32 |
Mapping a path for cancer precision medicine
|
Price, Douglas K
|
|
2017
|
18 |
11 |
p. 1444
|
article
|
| 33 |
Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer
|
Aggarwal, Rahul
|
|
2017
|
18 |
11 |
p. 1436-1437
|
article
|
| 34 |
Neo-adjuvant chemotherapy alone or with regional hyperthermia for soft-tissue sarcoma
|
Roussakow, Sergey
|
|
2017
|
18 |
11 |
p. e629
|
article
|
| 35 |
Neo-adjuvant chemotherapy alone or with regional hyperthermia for soft-tissue sarcoma – Authors' reply
|
Issels, Rolf D
|
|
2017
|
18 |
11 |
p. e630
|
article
|
| 36 |
Neoadjuvant chemotherapy in oesophageal adenocarcinoma
|
van Laarhoven, Hanneke W M
|
|
2017
|
18 |
11 |
p. e639
|
article
|
| 37 |
Neoadjuvant chemotherapy in oesophageal adenocarcinoma
|
Fornaro, Lorenzo
|
|
2017
|
18 |
11 |
p. e640
|
article
|
| 38 |
Neoadjuvant chemotherapy in oesophageal adenocarcinoma – Authors' reply
|
Alderson, Derek
|
|
2017
|
18 |
11 |
p. e641
|
article
|
| 39 |
New option for cisplatin-ineligible urothelial cancer
|
Dreicer, Robert
|
|
2017
|
18 |
11 |
p. 1428-1430
|
article
|
| 40 |
Oncolytic virus therapy in advanced melanoma
|
Gourd, Elizabeth
|
|
2017
|
18 |
11 |
p. e649
|
article
|
| 41 |
One for sorrow, two for joy
|
Swain, Kelley
|
|
2017
|
18 |
11 |
p. 1442-1443
|
article
|
| 42 |
Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study
|
Tammemagi, Martin C
|
|
2017
|
18 |
11 |
p. 1523-1531
|
article
|
| 43 |
Patients, data, and progress in cancer care
|
Chrischilles, Elizabeth A
|
|
2017
|
18 |
11 |
p. e624-e625
|
article
|
| 44 |
PD-1 inhibition in bone sarcoma and soft-tissue sarcoma
|
Mir, Olivier
|
|
2017
|
18 |
11 |
p. 1430-1431
|
article
|
| 45 |
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
|
Tawbi, Hussein A
|
|
2017
|
18 |
11 |
p. 1493-1501
|
article
|
| 46 |
Physical fitness and cancer
|
Estévez-López, Fernando
|
|
2017
|
18 |
11 |
p. e631
|
article
|
| 47 |
Priorities for cancer research in the USA
|
Simon, Gregory C
|
|
2017
|
18 |
11 |
p. e620-e621
|
article
|
| 48 |
Pyrotinib shows activity in metastatic breast cancer
|
Gourd, Elizabeth
|
|
2017
|
18 |
11 |
p. e643
|
article
|
| 49 |
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Catenacci, Daniel V T
|
|
2017
|
18 |
11 |
p. 1467-1482
|
article
|
| 50 |
Rising cancer drug costs in the USA
|
Burki, Talha Khan
|
|
2017
|
18 |
11 |
p. e652
|
article
|
| 51 |
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
|
Doi, Toshihiko
|
|
2017
|
18 |
11 |
p. 1512-1522
|
article
|
| 52 |
The Cancer Moonshot from a European perspective
|
Ciardiello, Fortunato
|
|
2017
|
18 |
11 |
p. e626
|
article
|
| 53 |
The Purple Drug Guide
|
Kinsey, Caroline
|
|
2017
|
18 |
11 |
p. 1441-1442
|
article
|
| 54 |
49th SIOP Congress
|
Landman, Allison
|
|
2017
|
18 |
11 |
p. 1440
|
article
|
| 55 |
Timing of androgen-deprivation therapy in prostate cancer
|
Del Priore, Giuseppe
|
|
2017
|
18 |
11 |
p. e633
|
article
|
| 56 |
Timing of androgen-deprivation therapy in prostate cancer
|
Nandagopal, Lakshminarayanan
|
|
2017
|
18 |
11 |
p. e634
|
article
|
| 57 |
Timing of androgen-deprivation therapy in prostate cancer – Author's reply
|
Duchesne, Gillian M
|
|
2017
|
18 |
11 |
p. e635
|
article
|
| 58 |
Treatment choice in EGFR-mutant non-small-cell lung cancer
|
Brueckl, Wolfgang M
|
|
2017
|
18 |
11 |
p. 1425-1426
|
article
|
| 59 |
UK radiologist staffing crisis reaches critical levels
|
Gourd, Elizabeth
|
|
2017
|
18 |
11 |
p. e651
|
article
|
| 60 |
What Cancer Taught Me
|
Denny, Victoria
|
|
2017
|
18 |
11 |
p. 1441
|
article
|
Journal description